Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P09012
UPID:
SNRPA_HUMAN
Alternative names:
-
Alternative UPACC:
P09012
Background:
U1 small nuclear ribonucleoprotein A (U1 snRNP A) plays a pivotal role in the pre-mRNA splicing process. It is a key component of the spliceosomal U1 snRNP complex, essential for the recognition of the pre-mRNA 5' splice-site and subsequent spliceosome assembly. This protein's interaction with pre-mRNA is crucial for the binding of U2 snRNP and the U4/U6/U5 tri-snRNP, facilitating the splicing process. Additionally, U1 snRNP A binds to stem loop II of U1 snRNA and may engage in the coupled pre-mRNA splicing and polyadenylation process, showing preference for the 5'-UGCAC-3' RNA motif.
Therapeutic significance:
Understanding the role of U1 small nuclear ribonucleoprotein A could open doors to potential therapeutic strategies, offering insights into the regulation of gene expression and the development of novel treatments.